PL2598500T3 - Kompozycje i sposoby hamowania szlaku JAK - Google Patents
Kompozycje i sposoby hamowania szlaku JAKInfo
- Publication number
- PL2598500T3 PL2598500T3 PL11745858T PL11745858T PL2598500T3 PL 2598500 T3 PL2598500 T3 PL 2598500T3 PL 11745858 T PL11745858 T PL 11745858T PL 11745858 T PL11745858 T PL 11745858T PL 2598500 T3 PL2598500 T3 PL 2598500T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibition
- compositions
- methods
- jak pathway
- jak
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36857010P | 2010-07-28 | 2010-07-28 | |
| EP11745858.8A EP2598500B1 (en) | 2010-07-28 | 2011-07-27 | Compositions and methods for inhibition of the jak pathway |
| PCT/US2011/045609 WO2012015972A1 (en) | 2010-07-28 | 2011-07-27 | Compositions and methods for inhibition of the jak pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2598500T3 true PL2598500T3 (pl) | 2021-11-29 |
Family
ID=44504225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11745858T PL2598500T3 (pl) | 2010-07-28 | 2011-07-27 | Kompozycje i sposoby hamowania szlaku JAK |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US8343954B2 (pl) |
| EP (1) | EP2598500B1 (pl) |
| JP (2) | JP6073221B2 (pl) |
| KR (1) | KR101937495B1 (pl) |
| CN (1) | CN103201280B (pl) |
| AR (2) | AR082408A1 (pl) |
| AU (1) | AU2011282742B2 (pl) |
| BR (1) | BR112013001632B1 (pl) |
| CA (1) | CA2804199C (pl) |
| DK (1) | DK2598500T3 (pl) |
| EA (1) | EA201390015A1 (pl) |
| ES (1) | ES2880622T3 (pl) |
| IL (1) | IL223855A (pl) |
| MX (2) | MX347331B (pl) |
| PL (1) | PL2598500T3 (pl) |
| PT (1) | PT2598500T (pl) |
| RU (1) | RU2672100C2 (pl) |
| TW (1) | TWI582090B (pl) |
| WO (1) | WO2012015972A1 (pl) |
| ZA (1) | ZA201300388B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EP2565193B1 (en) | 2009-01-23 | 2014-03-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| CA2804199C (en) | 2010-07-28 | 2020-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US9321763B2 (en) | 2012-04-04 | 2016-04-26 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| JP2016506930A (ja) * | 2013-01-25 | 2016-03-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患を処置するための化合物および方法 |
| EP2970275B1 (en) | 2013-03-14 | 2018-05-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US20160159774A1 (en) * | 2014-12-05 | 2016-06-09 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2016100452A2 (en) * | 2014-12-17 | 2016-06-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2017007658A1 (en) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| US20190060311A1 (en) * | 2017-08-24 | 2019-02-28 | Aclaris Therapeutics, Inc. | Compositions and methods for treatment of vitiligo |
| KR102808367B1 (ko) * | 2017-11-06 | 2025-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Hpk1 억제제로서 유용한 이소푸라논 화합물 |
| EP3802523A1 (en) | 2018-05-24 | 2021-04-14 | Astrazeneca AB | Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3h)-one |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN110078633B (zh) * | 2019-05-24 | 2021-05-11 | 爱斯特（成都）生物制药股份有限公司 | 一种4-氟-3-甲氧基-5-甲基苯胺盐酸盐制备方法 |
| CA3180623A1 (en) * | 2020-05-29 | 2021-12-02 | Changyou MA | Pyrimidine compound as axl inhibitor |
| KR20250053739A (ko) * | 2023-10-13 | 2025-04-22 | 주식회사유한양행 | 7,7-다이메틸푸로[3,4-b]피리딘-5(7H)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| WO2025109026A1 (en) * | 2023-11-21 | 2025-05-30 | Intervet International B.V. | Process for the preparation of 4-fluoro-3-methoxyaniline |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| DK0431519T3 (da) | 1989-12-04 | 1994-07-04 | Searle & Co | System til transdermal indgivelse af albuterol |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| US5700904A (en) | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| JP4886511B2 (ja) | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
| CN101115761B (zh) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物的前药及其应用 |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋキナーゼインヒビターおよびそれらの使用 |
| ZA200710206B (en) * | 2005-06-08 | 2009-12-30 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the JAK path-way |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8393954B2 (en) | 2006-12-29 | 2013-03-12 | Cfph, Llc | Top performers |
| US8456526B2 (en) * | 2006-08-25 | 2013-06-04 | Sportvision, Inc. | Video effect using movement within an image |
| US7947698B2 (en) * | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2009063240A1 (en) * | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| EP2565193B1 (en) * | 2009-01-23 | 2014-03-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| CA2804199C (en) * | 2010-07-28 | 2020-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8637038B2 (en) * | 2011-04-12 | 2014-01-28 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
-
2011
- 2011-07-27 CA CA2804199A patent/CA2804199C/en active Active
- 2011-07-27 BR BR112013001632-9A patent/BR112013001632B1/pt not_active IP Right Cessation
- 2011-07-27 DK DK11745858.8T patent/DK2598500T3/da active
- 2011-07-27 WO PCT/US2011/045609 patent/WO2012015972A1/en not_active Ceased
- 2011-07-27 RU RU2015122016A patent/RU2672100C2/ru active
- 2011-07-27 PT PT117458588T patent/PT2598500T/pt unknown
- 2011-07-27 AU AU2011282742A patent/AU2011282742B2/en not_active Ceased
- 2011-07-27 MX MX2013000757A patent/MX347331B/es active IP Right Grant
- 2011-07-27 PL PL11745858T patent/PL2598500T3/pl unknown
- 2011-07-27 CN CN201180036682.6A patent/CN103201280B/zh not_active Expired - Fee Related
- 2011-07-27 JP JP2013521954A patent/JP6073221B2/ja not_active Expired - Fee Related
- 2011-07-27 ES ES11745858T patent/ES2880622T3/es active Active
- 2011-07-27 EP EP11745858.8A patent/EP2598500B1/en active Active
- 2011-07-27 KR KR1020137004970A patent/KR101937495B1/ko not_active Expired - Fee Related
- 2011-07-27 EA EA201390015A patent/EA201390015A1/ru unknown
- 2011-07-27 US US13/192,344 patent/US8343954B2/en active Active
- 2011-07-28 TW TW100126853A patent/TWI582090B/zh not_active IP Right Cessation
- 2011-07-28 AR ARP110102733A patent/AR082408A1/es active IP Right Grant
-
2012
- 2012-11-26 US US13/685,433 patent/US9067925B2/en not_active Ceased
- 2012-12-25 IL IL223855A patent/IL223855A/en active IP Right Grant
-
2013
- 2013-01-15 ZA ZA2013/00388A patent/ZA201300388B/en unknown
- 2013-01-18 MX MX2020009397A patent/MX2020009397A/es unknown
-
2015
- 2015-05-29 US US14/725,932 patent/US9611260B2/en not_active Expired - Fee Related
- 2015-10-20 US US14/918,353 patent/USRE47396E1/en active Active
-
2016
- 2016-11-14 JP JP2016221423A patent/JP2017061518A/ja not_active Withdrawn
-
2017
- 2017-02-22 US US15/439,705 patent/US9920041B2/en active Active
-
2018
- 2018-02-08 US US15/892,224 patent/US10479783B2/en active Active
-
2019
- 2019-10-17 US US16/656,461 patent/US11174251B2/en active Active
-
2020
- 2020-09-02 AR ARP200102456A patent/AR119882A2/es unknown
-
2021
- 2021-10-05 US US17/494,370 patent/US20220024907A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214208A0 (en) | Compositions and methods for inhibition of the jak pathway | |
| ZA201300388B (en) | Compositions and methods for inhibition of the jak pathway | |
| IL263729A (en) | Preparations and methods for removing biofilms | |
| HRP20180829T1 (hr) | Spojevi tioacetata, pripravci i postupci za uporabu | |
| IL225672A0 (en) | Methods and compositions for polymerase inhibition | |
| ZA201301329B (en) | Novel compounds and compositions for the inhibition of nampt | |
| SG11201400668SA (en) | Wnt compositions and therapeutic uses of such compositions | |
| IL220939A (en) | Compounds that inhibit hdac and their pharmaceutical preparations | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| ZA201208265B (en) | Pharmaceutical compositions and methods of making same | |
| IL222291A0 (en) | Compositions and methods of synthesis of pyridinoylpiperidine | |
| EP2593571A4 (en) | SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME | |
| EP2370415A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH | |
| ZA201302952B (en) | Fungicidal compositions and methods of use | |
| ZA201407978B (en) | Compositions and methods for the alteration of xlhed phenotypes | |
| HK1196621A (en) | Wnt compositions and therapeutic uses of such compositions | |
| GB2499769A8 (en) | Composition for inhibiting the growth of mammalianhair | |
| HK1186478A (en) | Novel wnt compositions and therapeutic uses of such compositions | |
| GB201020463D0 (en) | Herbicidal compositions and methods of use | |
| EP2563802A4 (en) | COMPOSITIONS AND METHODS FOR MODIFYING GENE TRANSCRIPTION | |
| GB201007519D0 (en) | Means for inhibiting the expression of rragb | |
| HK1187278A (en) | Compositions and methods for the removal of biofilms | |
| GB201010083D0 (en) | Compositions and methods | |
| GB201009767D0 (en) | Compositions and methods |